BioCentury | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

China approves Keytruda monotherapy for 1L NSCLC China's National Medical Products Administration approved PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) as a monotherapy for first-line treatment of locally advanced or metastatic non-small...
BioCentury | Jan 5, 2019

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Aug 16, 2017
Emerging Company Profile

Aiming horizontal

SciBac Inc. is using old-school genetics to make therapeutic bacteria that can battle pathogenic organisms and antibiotic-resistant infections. The approach uses horizontal gene transfer to move therapeutic genes from newly discovered species into strains already...
BioCentury | Dec 15, 2014

Uphill road for Cubist CVRs

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics...
BioCentury | Dec 15, 2014
Company News

Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal valued at $9.5 billion. The cash offer of $102 per share, or $8.4 billion, represents a 37%...
BioCentury | Nov 27, 2014
Clinical News

Astellas: Data show fidaxomicin's efficacy, cost savings

Astellas Pharma Inc. (Tokyo:4503) said a pooled analysis showed that patients receiving fidaxomicin to treat Clostridium difficile infection (CDI) had reduced mortality, recurrence rates and healthcare costs compared with standard-of-care (SOC) vancomycin and metronidazole . The...
BioCentury | Apr 28, 2014

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...
BioCentury | Jan 27, 2014

Taiwan's biotech boom

As Taiwan's traditional growth sectors in IT, electronics and manufacturing have cooled, local investors have begun to look for new places to invest. Many are betting biotech is the next big thing. Indeed, the last...
BioCentury | Nov 25, 2013

Bugs in the clinic

Bugs in the clinic Newco Seres Health Inc. has emerged from stealth mode, and the Flagship Ventures startup believes it already has at least one leg up on other microbiome companies - a program in the...
BioCentury | Nov 4, 2013
Clinical News

Dificid fidaxomicin regulatory update

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published new guidelines recommending fidaxomicin for Clostridium difficile infection (CDI) in all patients suitable for oral antibiotic treatment. Specifically, fidaxomicin is recommended as first-line therapy...
Items per page:
1 - 10 of 181